• 1
    Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004; 54: 829.
  • 2
    AllenKA, HolladayEB, editors. Risk Management for the Cytology Laboratory. Raleigh, NC: American Society for Cytotechnology; 2002.
  • 3
    Ronco G SN, Giorgi-Rossi P, Zappa M, et al. New Technologies for Cervical Cancer Working Group. 2006. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst. 2006; 98: 765774.
  • 4
    Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA. 2001; 285: 15001505.
  • 5
    Klaes R, Benner A, Friedrich T, et al. p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol. 2002; 26: 13891399.
  • 6
    Sahebali S, Depuydt CE, Segers K, et al. P16INK4a as an adjunct marker in liquid-based cervical cytology. Int J Cancer. 2004; 108: 871876.
  • 7
    Bibbo M, Klump WJ, DeCecco J, Kovatich AJ. Procedure for immunocytochemical detection of P16INK4A antigen in thin-layer, liquid-based specimens. Acta Cytol. 2002; 46: 2529.
  • 8
    Sherr CJ. Principles of tumor suppression. Cell. 2004; 116: 235246.
  • 9
    Saqi A, Pasha TL, McGrath CM, Yu GH, Zhang P, Gupta P. Overexpression of p16INK4A in liquid-based specimens (SurePath) as marker of cervical dysplasia and neoplasia. Diagn Cytopathol. 2002; 27: 365370.
  • 10
    Murphy N, Ring M, Killalea AG, et al. p16INK4A as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and ThinPrep smears. J Clin Pathol. 2003; 56: 5663.
  • 11
    Agoff SN, Lin P, Morihara J, Mao C, Kiviat NB, Koutsky LA. p16(INK4a) expression correlates with degree of cervical neoplasia: a comparison with Ki-67 expression and detection of high-risk HPV types. Mod Pathol. 2003; 16: 665673.
  • 12
    Sandri MT, Lentati P, Benini E, et al. Comparison of the Digene HC2 Assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples. J Clin Microbiol. 2006; 44: 21412146.
  • 13
    Negri GM, Rigo B, Vittadello F, Egarter-Vigl E, Mian C. Human papillomavirus typing with Hybrid Capture II on archived liquid-based cytologic specimens: is HPV typing always reproducible? Am J Clin Pathol. 2004; 122: 9093.
  • 14
    Akpolat I, Smith DA, Ramzy I, Chirala M, Mody DR. The utility of p16INK4a and Ki-67 staining on cell blocks prepared from residual thin-layer cervicovaginal material. Cancer (Cancer Cytopathol). 2004; 102: 142149.
  • 15
    Bibbo M, DeCecco J, Kovatich AJ. P16INK4A as an adjunct test in liquid-based cytology. Anal Quant Cytol Histol. 2003; 25: 811.
  • 16
    Branca M, Ciotti M, Santini D, et al. p16(INK4A) expression is related to grade of CIN and high-risk human papillomavirus but does not predict virus clearance after conization or disease outcome. Int J Gynecol Pathol. 2004; 23: 354365.
  • 17
    Geradts J, Hruban RH, Schutte M, Kern SE, Maynard R. Immunohistochemical p16INK4a analysis of archival tumors with deletion, hypermethylation, or mutation of the CDKN2/MTS1 gene. A comparison of four commercial antibodies. Appl Immunohistochem Mol Morphol. 2000; 8: 7179.
  • 18
    Ishikawa M, Fujii T, Masumoto N, et al. Correlation of p16INK4A overexpression with human papillomavirus infection in cervical adenocarcinomas. Int J Gynecol Pathol. 2003; 22: 378385.
  • 19
    Keating JT, Cviko A, Riethdorf S, et al. Ki-67, cyclin E, and p16INK4 are complimentary surrogate biomarkers for human papillomavirus-related cervical neoplasia. Am J Surg Pathol. 2001; 25: 884891.
  • 20
    Kim YT, Cho NH, Park SW, Kim JW. Underexpression of cyclin-dependent kinase (CDK) inhibitors in cervical carcinoma. Gynecol Oncol. 1998; 71: 3845.
  • 21
    Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer. 2001; 92: 276284.
  • 22
    Masumoto N, Fujii T, Ishikawa M, et al. P16 overexpres sion and human papillomavirus infection in small cell carcinoma of the uterine cervix. Hum Pathol. 2003; 34: 778783.
  • 23
    Negri G, Egarter-Vigl E, Kasal A, Romano F, Haitel A, Mian C. p16INK4a is a useful marker for the diagnosis of adenocarcinoma of the cervix uteri and its precursors: an immunohistochemical study with immunocytochemical correlations. Am J Surg Pathol. 2003; 27: 187193.
  • 24
    Negri G, Vittadello F, Romano F, et al. p16INK4a expression and progression risk of low-grade intraepithelial neoplasia of the cervix uteri. Virchows Arch. 2004; 445: 616620.
  • 25
    Nieh S, Chen SF, Chu TY, Lai HC, Fu E. Expression of p16 INK4A in Papanicolaou smears containing atypical squamous cells of undetermined significance from the uterine cervix. Gynecol Oncol. 2003; 91: 201208.
  • 26
    Nieh S, Chen SF, Chu TY, Lai HC, Fu E. Expression of p16INK4A in Pap smears containing atypical glandular cells from the uterine cervix. Acta Cytol. 2004; 48: 173180.
  • 27
    Pientong C, Ekalaksananan T, Swadpanich U, et al. Immunocytochemical detection of p16INK4a protein in scraped cervical cells. Acta Cytol. 2003; 47: 616623.
  • 28
    Riethdorf L, Riethdorf S, Lee KR, Cviko A, Loning T, Crum CP. Human papillomaviruses, expression of p16, and early endocervical glandular neoplasia. Hum Pathol. 2002; 33: 899904.
  • 29
    Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. Immunohistochemical overexpression of p16 protein associated with intact retinoblastoma protein expression in cervical cancer and cervical intraepithelial neoplasia. Pathol Int. 1998; 48: 580585.
  • 30
    Tringler B, Gup CJ, Singh M, et al. Evaluation of p16INK4a and pRb expression in cervical squamous and glandular neoplasia. Hum Pathol. 2004; 35: 689696.
  • 31
    Tsuda H, Hashiguchi Y, Nishimura S, Kawamura N, Inoue T, Yamamoto K. Relationship between HPV typing and abnormality of G1 cell cycle regulators in cervical neoplasm. Gynecol Oncol. 2003; 91: 476485.
  • 32
    Volgareva G, Zavalishina L, Andreeva Y, et al. Protein p16 as a marker of dysplastic and neoplastic alterations in cervical epithelial cells. BMC Cancer. 2004; 4: 58.
  • 33
    von Knebel Doeberitz M. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer. 2002; 38: 22292242.
  • 34
    Wang HL, Lu DW. Detection of human papillomavirus DNA and expression of p16, Rb, and p53 proteins in small cell carcinomas of the uterine cervix. Am J Surg Pathol. 2004; 28: 901908.
  • 35
    Yoshida T, Fukuda T, Sano T, Kanuma T, Owada N, Nakajima T. Usefulness of liquid-based cytology specimens for the immunocytochemical study of p16 expression and human papillomavirus testing: a comparative study using simultaneously sampled histology materials. Cancer (Cancer Cytopathol). 2004; 102: 100108.
  • 36
    Zielinski GD, Snijders PJ, Rozendaal L, et al. The presence of high-risk HPV combined with specific p53 and p16INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix. J Pathol. 2003; 201: 535543.
  • 37
    Kanao H, Enomoto T, Ueda Y, et al. Correlation between p14(ARF)/p16(INK4A) expression and HPV infection in uterine cervical cancer. Cancer Lett. 2004; 213: 3137.
  • 38
    Williams IR, Lorincz AT, O'Hara A. Novel approach to molecular diagnosis of human papillomavirus-related diseases. In: Application USP. Gaithersburg, MD: Digene Corporation; 2004.
  • 39
    Trunk MJ, Dallenbach-Hellweg G, Ridder R, et al. Morphologic characteristics of p16INK4a-positive cells in cervical cytology samples. Acta Cytol. 2004; 48: 771782.
  • 40
    Guo M, Hu L, Baliga M, He Z, Hughson MD. The predictive value of p16(INK4a) and Hybrid Capture 2 human papillomavirus testing for high-grade cervical intraepithelial neoplasia. Am J Clin Pathol. 2004; 122: 894901.